Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
2.785
-0.125 (-4.30%)
Mar 31, 2025, 1:31 PM EDT - Market open
Savara Employees
Savara had 37 employees as of December 31, 2023. The number of employees increased by 9 or 32.14% compared to the previous year.
Employees
37
Change (1Y)
9
Growth (1Y)
32.14%
Revenue / Employee
n/a
Profits / Employee
-$2,591,378
Market Cap
586.17M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SVRA News
- 4 days ago - Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Business Wire
- 4 days ago - Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Business Wire
- 4 days ago - Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 14 days ago - Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 - Business Wire
- 25 days ago - Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 27 days ago - Savara Announces Participation in the Leerink Global Healthcare Conference - Business Wire
- 6 weeks ago - Savara Announces New Employment Inducement Grant - Business Wire
- 2 months ago - Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research - Business Wire